OKLAHOMA CITY, OK--(Marketwired - Oct 1, 2013) - Cytovance Biologics, a leading full-service contract manufacturer ("CMO") of mammalian and microbial biologics, announces that they have entered into a manufacturing agreement with Translational Sciences, Inc., a Memphis, Tennessee-based clinical stage biopharmaceutical company.
"By entering this agreement with Cytovance Biologics, Translational Sciences has achieved another milestone in the development of Stromab, a first-in-class therapeutic antibody for treatment of ischemic stroke, one of the major causes of death and disability in the U.S. and worldwide," said Dr. Karen Lee of Translational Sciences, Inc.
"Cytovance's state-of-the-art facilities and experienced staff are prepared to deliver the highest quality of manufacturing services for Translational Sciences," said Darren Head, President and Chief Executive Officer of Cytovance Biologics. "We are pleased to be a part of a novel discovery to treat acute stroke which is one of the leading causes of death in people worldwide."
About Translational Sciences, Inc.
Translational Sciences, Inc. is a university-associated, biotechnology company that focuses on the development of novel therapies to reduce the costs of death and disability associated with vascular diseases. Translational Sciences, Inc. has been the recipient of research funding from the National Institutes of Neurologic Diseases and Stroke of the National Institutes of Health. For further information regarding Translational Sciences, Inc., contact firstname.lastname@example.org.
About Cytovance Biologics
Cytovance Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
Learn more about Cytovance Biologics at www.cytovance.com.